In vivo administration of a DLGAP1‐AS2‐targeting ASO in patient‐derived xenograft (PDX) models of squamous cell carcinoma (SCC) sensitized SCC samples to cisplatin treatment.70 Here, DLGAP1 is linked to squamous cell carcinoma.